Studying the risk of breast cancer returning after surgery
Part of Cancer, Skin clinical trials.
This study looks at real-world patterns and the risk of cancer returning after surgery in people with early-stage breast cancer that is hormone receptor positive and HER2 negative. By reviewing medical records, researchers hope to learn more about what affects recurrence to improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with breast cancer (your first time) between 2010 and 2023.
- You were 18 or older when you were first diagnosed.
- Your cancer was stage I, II, or III at diagnosis (not stage 0 or stage IV).
- Your cancer is hormone receptor positive (grows with hormones like estrogen or progesterone).
- Your cancer is HER2 negative (tests negative for a protein that makes cancer grow faster).
- You had surgery to remove the tumor (such as a lumpectomy or mastectomy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different treatment plans after surgery for people with HER2-positive breast cancer who still have cancer cells remaining after initial chemo and trastuzumab. It aims to see which approach helps improve outcomes.
This trial studies early, hormone receptor–positive, HER2-negative breast cancer and looks at a group with “high clinical risk” but “low genetic (tumor) risk.” It may help researchers understand which patients may benefit most from treatment decisions guided by genetic tumor testing.
This study looks at what makes early breast cancer (that hasn't spread beyond the breast or nearby lymph nodes) more likely to come back after treatment. It uses your medical records to build a better way to predict recurrence, which could help personalize follow-up care.
This study follows people who have had breast cancer come back in the same area after their first surgery. It aims to learn more about local recurrence to improve future treatment.
This trial compares two treatment approaches in people with high-risk hormone-positive, HER2-negative breast cancer that has spread to certain lymph nodes. It looks at which option works best to lower cancer returning and to control the disease after surgery and initial chemotherapy.
This trial looks at factors that may predict whether hormone receptor–positive breast cancer will come back after you’ve already completed 5 years of hormone (endocrine) therapy. It may help identify who benefits most from longer treatment and follow-up.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.